The history and rise of Hyperloop UC
Author Gulnaaz Afzal is a design engineer for Hyperloop UC, shares key highlights
Hyperloop UC started as a sketch of the back of a napkin, drawn by the team’s founder, Dhaval Shiyani. Shiyani accepted Elon Musk’s challenge to create a revolutionary transportation system.
With the help of talented, passionate, and driven students from engineering, marketing, graphic design, and business backgrounds, the Hyperloop UC team has secured a spot in the top 40 teams every year since the 2016 initial SpaceX competition.
Read more about the team's journey to create a revolutionary technology on LinkedIn.
Author Gulnaaz Afzal is a design engineer for Hyperloop UC.
Featured image at top: The Hyperloop UC team gathers at a competition. Photo/provided.
Related Stories
Sugar overload killing hearts
November 10, 2025
Two in five people will be told they have diabetes during their lifetime. And people who have diabetes are twice as likely to develop heart disease. One of the deadliest dangers? Diabetic cardiomyopathy. But groundbreaking University of Cincinnati research hopes to stop and even reverse the damage before it’s too late.
App turns smartwatch into detector of structural heart disease
November 10, 2025
An app that uses an AI model to read a single-lead ECG from a smartwatch can detect structural heart disease, researchers reported at the 2025 Scientific Sessions of the American Heart Association. Although the technology requires further validation, researchers said it could help improve the identification of patients with heart failure, valvular conditions and left ventricular hypertrophy before they become symptomatic, which could improve the prognosis for people with these conditions.
Combination immunotherapy helps overcome melanoma treatment resistance
November 10, 2025
MSN highlighted research led by the University of Cincinnati Cancer Center's Trisha Wise-Draper showing a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.